Lixivaptan
Overview
We are developing lixivaptan, an oral, non-peptide, new chemical agent that is designed to selectively suppress the activity of the hormone vasopressin at the V2 receptor with potential to avoid safety issues associated with the only drug approved for the treatment of ADPKD. Lixivaptan is currently in a Phase 3 registrational trial for the treatment of ADPKD.
Reason to Believe in Target
Precedented Human Activity
Epidemiology | Disease |
---|---|
Epidemiology |
Disease Autosomal dominant polycystic kidney disease (ADPKD) |
Leadership
Alex Martin, MBA – Chief Executive Officer
Lorenzo Pellegrini, PhD – Founder & Chief Operating Officer
Neil H. Shusterman, MD – Chief Medical Officer